Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25

Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.